Dehydration

Quoin Pharmaceuticals and Genpharm Services Sign Exclusive License and Distribution Agreement for Quoin’s Lead Asset, QRX003

Retrieved on: 
Thursday, November 11, 2021
Dehydration, Private Securities Litigation Reform Act, Netherton syndrome, Degenerative disease, NASDAQ, Project, Disease, Distribution, Peeling skin syndrome, Growth, Mutation, Forward-looking statement, MENA, SPINK5, Risk, Epidermolysis bullosa, Patient, Company, GLOBE, Solution, Therapy, Infection, SEC, Lists of diseases, Allergy, Specialty, Asthma, Dermatitis, Pharmaceutical industry

Under the terms of the agreement, Genpharm Services has exclusive rights to commercialize QRX003 in the Middle East and North Africa region, upon the receipt of regulatory approvals in both territories.

Key Points: 
  • Under the terms of the agreement, Genpharm Services has exclusive rights to commercialize QRX003 in the Middle East and North Africa region, upon the receipt of regulatory approvals in both territories.
  • Upon approval and launch of the product, Quoin will be entitled to a revenue sharing arrangement on net sales of the product.
  • The companies have also entered into an exclusive Supply Agreement, under which Quoin is obligated to manufacture and supply the product to Genpharm Services.
  • Dr. Michael Myers, Chief Executive Officer of Quoin, commented, The licensing agreement with Genpharm is the second licensing agreement that weve announced for QRX003, which we are developing as a potential treatment for Netherton Syndrome.

Adecoagro reported Adjusted EBITDA of $157.0 million in 3Q21 and $367.6 million in 9M21, 53.7% and 50.4%higher year-over-year, respectively.

Retrieved on: 
Wednesday, November 10, 2021
Mission statement, Efficiency, Ethanol, Lluís Companys, Achievement, Share repurchase, Industry, Reuters, Policy, International Financial Reporting Standards, Lubricant, Argentine peso, Cushman & Wakefield, Growth, Investment, Phrase, International, IFRS, Non, IAS, BIOS, Program, Frost, EBITDA, Public expenditure, Sale, Rice, Argentines, Internet, Company, NYSE, Weather, Income, Bloomberg, TRS, Dehydration, Cryptocurrency, Renewable energy, Agriculture, Security (finance), Holding company, Public relations

In our Sugar, Ethanol & Energy business, Adjusted EBITDA reached $138.1 million in 3Q21, 59.8%, or $51.7 million higher compared to the same period of last year.

Key Points: 
  • In our Sugar, Ethanol & Energy business, Adjusted EBITDA reached $138.1 million in 3Q21, 59.8%, or $51.7 million higher compared to the same period of last year.
  • On a year-to-date basis, Adjusted EBITDA reached $269.8 million, 56.2% higher compared to the same period of last year.
  • Adjusted EBITDA in our Crops segment was $13.7 million in 3Q21, $7.9 million higher compared to the same period of last year.
  • However, during 9M21 Adjusted EBITDA stood at $40.7 million, 37.9% or $11.2 million higher than during 9M20.

Quoin Pharmaceuticals Signs Exclusive Licensing and Distribution Agreement with AFT Pharmaceuticals for its Lead Asset, QRX003

Retrieved on: 
Monday, November 8, 2021
Dehydration, Private Securities Litigation Reform Act, Netherton syndrome, AFT, NASDAQ, Project, Distribution, Peeling skin syndrome, Growth, Mutation, Forward-looking statement, SPINK5, Risk, Epidermolysis bullosa, Sale, Patient, Company, GLOBE, Infection, SEC, Lists of diseases, Allergy, Asthma, Dermatitis, OTC, Pharmaceutical industry

ASHBURN, Va., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, today announced that it has entered into an exclusive License and Distribution Agreement with AFT Pharmaceuticals Ltd. (“AFT”) for QRX003, the Company's investigational treatment for Netherton Syndrome, a rare and devastating genetic disease.

Key Points: 
  • Under the terms of the agreement, AFT has exclusive rights to commercialize QRX003 in Australia and New Zealand, upon the receipt of regulatory approvals in both territories.
  • The companies have also entered into an exclusive Supply Agreement, under which Quoin is obligated to manufacture and supply the product to AFT.
  • Dr. Michael Myers, Chief Executive Officer of Quoin, commented, The licensing agreement with AFT is the first licensing agreement for QRX003, which we are developing as a potential treatment for Netherton Syndrome.
  • AFT is excited to work with Quoin Pharma to make this important treatment available to patients in Australia and New Zealand.

Grifols introduces ALBUTEIN FlexBag™ (Albumin [Human] U.S.P.) in 5% and 25% concentrations, a more convenient option for healthcare professionals

Retrieved on: 
Thursday, November 4, 2021
Safety, Anemia, Plasticizer, History, EUR, Commercial Operating System (COS), MCE, Multimedia, Health, GRF, ADR, Allergy, PVC, Coagulation, Blood, Transfusion medicine, Ovarian hyperstimulation syndrome, Creutzfeldt–Jakob disease, Hematology, Food, Water, Regulation of tobacco by the U.S. Food and Drug Administration, Respiratory distress syndrome, S.A, Solution, Plasmapheresis, Pharmacy, Hospital, Excipient, Red blood cell, Carbon, Dehydration, Hypersensitivity, CJD, Hypovolemia, Phthalate, Sale, Legislation, Heart failure, Patient, Heart, Plasma, Hemolysis, Anaphylaxis, Pulmonary edema, Paracentesis, Hypervolemia, NASDAQ, FDA, Electrolyte, Adult, Polyvinyl chloride, DEHP, Blood product, Medical device, Birth control

"This step forward will expand and differentiate Grifols' industry-leading albumin portfolio to benefit patients and bring convenient, flexible container options to our customers."

Key Points: 
  • "This step forward will expand and differentiate Grifols' industry-leading albumin portfolio to benefit patients and bring convenient, flexible container options to our customers."
  • Sustainability was key for Grifols when developing the environmentally friendly ALBUTEIN FlexBag.
  • Both the ALBUTEIN FlexBag flexible container and protective overwrap are latex-free and do not contain polyvinyl chloride (PVC), diethylhexyl phthalate (DEHP) or other plasticizers.
  • The launch of ALBUTEIN FlexBag solidifies Grifols commitment to R+D+i, which has enabled the company to further expand its industry-leading portfolio of plasma-derived medicines for patients and healthcare professionals.

Ironwood Pharmaceuticals Expands Pipeline by Signing an Option Agreement to Acquire an Exclusive License with COUR Pharmaceuticals to Develop and Commercialize CNP-104 for the Treatment of Primary Biliary Cholangitis (PBC) in the U.S.

Retrieved on: 
Thursday, November 4, 2021
Health, Other Health, General Health, Research, Pharmaceutical, Science, Safety, Medication, Research, Biotechnology, Technology, Ironwood Pharmaceuticals, LinkedIn, PBC, Abdominal pain, Gastrointestinal disease, Bloating, IBS-C, Drug development, Irritable bowel syndrome, Pathology, Dehydration, Primary biliary cholangitis, Twitter, History, CNP, Gastroenterology, NASDAQ, Patient, FDA, Autoimmunity, Food, Exercise, Risk, Degenerative disease, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Medicine, GC, AbbVie, CIC, Disease management, Adult, Company, GC-C, Autoimmune disease, Standard of care, Clinical trial, Constipation, Trial of the century, Diarrhea, IQVIA, IND, Pain, Nasdaq, Death, Mortality, AstraZeneca, Heart, Liver, Incidence, Pharmaceutical industry, Vaccine, Health insurance, Ironwood Pharmaceuticals, LINZESS (linaclotide), IRONWOOD PHARMACEUTICALS, LINZESS (LINACLOTIDE)

This option agreement highlights our focus on prudently allocating capital to value enhancing opportunities while maintaining the flexibility to simultaneously execute on our other strategic priorities.

Key Points: 
  • This option agreement highlights our focus on prudently allocating capital to value enhancing opportunities while maintaining the flexibility to simultaneously execute on our other strategic priorities.
  • After reviewing the data from the Initial Study, the Company has the right to exercise the option.
  • We are excited to collaborate with Ironwood given their commercial infrastructure and history of GI innovation, said COUR CEO John Puisis.
  • Pursuant to the terms of the agreement, Ironwood will pay COUR approximately $20 million in upfront and near-term payments associated with the Initial Study.

Human Amnion-Chorion Membrane Preserves Alveolar Ridge

Retrieved on: 
Tuesday, November 2, 2021
University of Illinois at Chicago College of Dentistry, Aesthetics, Volunteering, University, College, Dental implant, Patient, Comparison, Clinical, Synthetic control method, Oral, Prosthodontics, University of Kentucky, Dehydration, Extraction (chemistry), American Academy, Journal, JOI, Dentistry

Preservation of the alveolar ridge helps to secure bone structure essential for the eventual successful dental implant placement.

Key Points: 
  • Preservation of the alveolar ridge helps to secure bone structure essential for the eventual successful dental implant placement.
  • The patients were split into a 21-person experimental group receiving a human amnion-chorion membrane (experimental) and a 22-person control group receiving a bovine collagen membrane (control).
  • The findings of this study suggest that using a human amnion-chorion membrane to aid in alveolar ridge preservation had no significant difference from using the traditional type 1 bovine collagen membrane.
  • Full text of the article, "Comparison of Dehydrated Human Amnion-Chorion and Type 1 Bovine Collagen Membranes in Alveolar Ridge Preservation: A Clinical and Histological Study" Journal of Oral Implantology, Vol.

Pelican Hooked and Snared in Fishing Line Rescued and Recovering at Oakland Zoo Veterinary Hospital

Retrieved on: 
Tuesday, November 2, 2021
Turtle, International Bird Rescue, Zoology, Anemia, Zoo, Dehydration, Habit, Organization, Oakland Zoo, Starvation, VP, State Veterinary Service, Bird, National Audubon Society, Injury, Animal, Neck, Medicine, Veterinary medicine, Dentistry, Hunting, Trapping

Upon arrival at the Zoo, veterinary staff examined the bird, administered fluids, conducted a blood draw, and examined the injured area on the neck.

Key Points: 
  • Upon arrival at the Zoo, veterinary staff examined the bird, administered fluids, conducted a blood draw, and examined the injured area on the neck.
  • From initial observations, the veterinary staff determined the pelican suffered from dehydration, starvation, and based on the bloodwork appeared to have possible anemia.
  • After examinations, Dr. Alex Herman, VP of Veterinary Service sat Oakland Zoo removed the one-inch barbed fishing hook from the pelican's neck.
  • Proper disposal of fishing line is crucial, and every citizen can help by picking up any fishing items found in nature", says Amy Gotliffe, Vice President of Conservation at Oakland Zoo.

First Structured Water Device Certified to Create H3O2 - Breakthrough Water Treatment System with No Replacement Parts

Retrieved on: 
Tuesday, October 26, 2021
Consciousness, Commerce, University, Device, Element, University of Washington, Dehydration, Partnership, Patient, Wells Enterprises, AQUA, Cold Water School, Pillar (car), Whole-house fan, Hydrate, Recreational vehicle, Cell–cell interaction, Maintenance, LLC, Electricity, CEO, Skin, Political movement, Cell, Toxicity, Nature, Lymph, Liver, Four Pillars, Water, Plumbing, Aluminium, Management

HyFo Lab, LLC tests verify the presence of structured water, or fourth phase water.

Key Points: 
  • HyFo Lab, LLC tests verify the presence of structured water, or fourth phase water.
  • "Finally, with the Aqua Energizer, people have confidence that their device has been proven to create structured water."
  • The Wellness Enterprise is a global leader in structured water with the highest form of water science, purification and treatment devices on the market.
  • For further information about structured water, explore the Water School and the Hydrate Now Course on TheWellnessEnterprise.com .

Altitude Is a Multifunctional Drink Ideal for Short, Dark Winter Days

Retrieved on: 
Friday, October 22, 2021
Altitude, Research, Crash, Aircraft, Stomach, Darkness, Dehydration, Anxiety, History, Drinking, Energy, Intention, Espresso, Nutritionist, Rest, Coffee

Altitude is a great way to stay healthy and energized during the cold, dark months of the year.

Key Points: 
  • Altitude is a great way to stay healthy and energized during the cold, dark months of the year.
  • However, the multifunctional tonic was originally created for a distinct purpose which also had to do with tired, long workdays.
  • This means American consumers can also finally tap into the energy tonic's potent effect as they face the long, dark winter days ahead.
  • About Altitude: Altitude is an organic energy tonic owned and produced by the Austrian/Italian company PilotsFriend.

Ron Simon & Associates Files Nation's First Onion Salmonella Lawsuit Against ProSource Inc. for Onion Salmonella Outbreak Sickening 652 Consumers

Retrieved on: 
Friday, October 22, 2021
Food safety, Abdominal pain, Dehydration, ABC, Legislation, FDA, Television, Nausea, Eating, Vomiting, Restaurant, Diarrhea, Multimedia, Centers for Disease Control and Prevention, NBC, Onion, CDC, FOX, Hospital, CNN, CBS, Publication, Salmonellosis, Disease, Center, Bottled water, Fast food, Poultry, Pharmaceutical industry

The lawsuit was filed against ProSource Inc. in Washington County, Idaho on behalf of Terry McLean, who purchased a hot dog with onions at a local establishment.

Key Points: 
  • The lawsuit was filed against ProSource Inc. in Washington County, Idaho on behalf of Terry McLean, who purchased a hot dog with onions at a local establishment.
  • He was interviewed by county health officials who confirmed he was part of the ProSource Inc. onions Salmonella Oranienburg Outbreak.
  • Mr. Simon and his law firm have established a Salmonella Claim Center to assist victims in the outbreak.
  • For media inquiries or more information on the Salmonella outbreak and ongoing litigation, please contact Ron Simon directly at (713) 819-8116 or [email protected] .